// App-Quantinova.ai

513 : Time to Achieve Moderate/Low Disease Activity and Remission in RA Patients on Baricitinib Compared to Adalimumab, Methotrexate, and Placebo

Researchers

Presenter

  • Edward C. Keystone

Principal Investigators

  • Maxime Dougados

  • Eric M. Ruderman

  • Baojin Zhu

  • Pedro Lopez-Romero

  • Hanne Lund

  • Anabela Cardoso

  • Douglas E. Schlichting

  • Pindaro Martinez Osuna

  • Robert Ortmann

  • Tore K. Kvien

Medical Centers

  • University of Toronto, Toronto, ON, Canada

  • Paris Descartes University, Cochin Hospital, Paris, France

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • Eli Lilly and Company, Indianapolis, IN

  • Europe Research Center, Eli Lilly and Company, Madrid, Spain

  • Eli Lilly Norge A.S., Oslo, Norway

  • Diakonhjemmet Hospital, Oslo, Norway

Locations

  • Canada

  • France

  • United States

  • Spain

  • Norway

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Methotrexate

  • Baricitinib

  • Adalimumab

  • BARI

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved